Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Equity Ratio (2019 - 2025)

Silence Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.47 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 28.33% year-over-year to 0.47; the TTM value through Dec 2025 reached 0.47, down 28.33%, while the annual FY2025 figure was 0.47, 28.33% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.47 at Silence Therapeutics, down from 0.5 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.66 in Q4 2024 and bottomed at 0.09 in Q4 2021.
  • The 5-year median for Equity Ratio is 0.49 (2025), against an average of 0.41.
  • The largest annual shift saw Equity Ratio surged 263.95% in 2024 before it decreased 28.33% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.09 in 2021, then skyrocketed by 131.65% to 0.21 in 2022, then decreased by 11.49% to 0.18 in 2023, then skyrocketed by 263.95% to 0.66 in 2024, then fell by 28.33% to 0.47 in 2025.
  • Per Business Quant, the three most recent readings for SLN's Equity Ratio are 0.47 (Q4 2025), 0.5 (Q3 2025), and 0.57 (Q2 2025).